INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 195 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $204,000 | -67.5% | 1,616 | -63.3% | 0.01% | -60.7% |
| Q2 2016 | $627,000 | +200.0% | 4,400 | +31328.6% | 0.03% | +300.0% |
| Q4 2015 | $209,000 | -3.7% | 14 | -98.4% | 0.01% | +75.0% |
| Q2 2015 | $217,000 | -4.0% | 900 | +12.5% | 0.00% | -42.9% |
| Q1 2015 | $226,000 | -68.6% | 800 | -73.7% | 0.01% | -69.6% |
| Q3 2014 | $720,000 | -12.4% | 3,044 | -12.4% | 0.02% | -39.5% |
| Q2 2014 | $822,000 | – | 3,474 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |